Multiple Sclerosis Drugs - Thailand

Thailand

Thailand's Multiple Sclerosis Drugs market is anticipated to witness a significant increase in revenue, with projections estimating it to reach US$35.28m in 2024.
Furthermore, the market is expected to display a steady annual growth rate (CAGR 2024-2029) of 1.31%.
This growth trajectory indicates that the market volume will expand to approximately US$37.66m by 2029.
In a global context, it is noteworthy that United States will generate the highest revenue in the Multiple Sclerosis Drugs market, with an impressive figure of US$11,770.00m expected in 2024.
Thailand's growing healthcare infrastructure and rising awareness about Multiple Sclerosis have led to an increasing demand for advanced drugs in the market.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market has been growing steadily in Thailand, with a significant increase in demand for such drugs in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Thailand prefer to use drugs that are effective in treating their condition. They also prefer drugs that have fewer side effects and are affordable. Patients are willing to pay a premium for drugs that meet these criteria.

Trends in the market: The Multiple Sclerosis Drugs market in Thailand has been growing due to an increase in the number of patients diagnosed with Multiple Sclerosis. There has also been an increase in the availability of drugs for the treatment of Multiple Sclerosis. The market has seen the introduction of new drugs that are more effective in treating the condition.

Local special circumstances: The Thai government has been working to improve healthcare services in the country. This has led to an increase in the availability of drugs for the treatment of Multiple Sclerosis. The government has also been working to reduce the cost of healthcare services, making it more affordable for patients.

Underlying macroeconomic factors: Thailand has a growing economy, which has led to an increase in the standard of living of its citizens. This has led to an increase in demand for healthcare services, including drugs for the treatment of Multiple Sclerosis. The government has been investing in the healthcare sector, which has led to an increase in the availability of drugs and healthcare services.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.